Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Androgen receptor CAG repeats, non-random X chromosome inactivation, and loss of heterozygosity at Xq25 in relation to breast cancer risk

Authors: Hui-Tzu Chen, Yao-Chung Wu, Shou-Tung Chen, Hsien-Chang Tsai, Yi-Chih Chien

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

The aim of this study was to examine the association of non-random X chromosome inactivation (XCI) and loss of heterozygosity (LOH) at Xq25 with breast cancer development.

Methods

Seventy-nine breast cancer patients, 39 female lung cancer patients, 30 other cancer patients and 77 healthy females were analysed for LOH using a panel of 11 microsatellite markers spanning Xq25. The androgen receptor (AR) gene was chosen as an XCI marker.

Results

LOH of at least one microsatellite locus at Xq25 was identified in 46/65 breast cancers examined, while only 10/25 cancers of other origins demonstrated LOH in this region (p = 0.014). The critical deletion region in breast cancer was around marker DXS1047 (47.23%). Moreover, we found that tissues from eight breast cancers showed LOH at all of the informative loci tested at Xq25, while the other 38 showed partial (interstitial or telomeric) alterations at Xq25. Interestingly, the pattern of XCI of these eight breast cancers tended to be non-random. We estimated the frequencies of AR alleles and found that women with two long AR alleles (≥21 CAG repeats) had an increased risk of developing breast cancer, while those with two short AR alleles (<21 CAG repeats) were likely to be normal (p = 0.00069).

Conclusions

The extraordinary high frequencies of LOH at Xq25 found in this study strongly imply that there might be one or more tumour suppressor genes (TSGs) related to the development of breast cancer at Xq25 in the Taiwanese female population.
Appendix
Available only for authorised users
Literature
1.
Brown CJ: Role of the X chromosome in cancer. J Natl Cancer Inst. 1996, 88: 480-482. 10.1093/jnci/88.8.480.CrossRefPubMed
2.
Heard E, Clerc P, Avner P: X-chromosome inactivation in mammals. Annu Rev Genet. 1997, 31: 571-610. 10.1146/annurev.genet.31.1.571.CrossRefPubMed
3.
Parolini O, Ressmann G, Hass OA, Pawlowsky J, Gadner H, Knapp W, Holter W: X-linked Wiskott-Aldrich syndrome in a girl. N Engl J Med. 1998, 338: 291-295. 10.1056/NEJM199801293380504.CrossRefPubMed
4.
Clarke JT, Greer WJ, Strasberg PM, Pearce RD, Skomorowski MA, Ray PN: Hunter disease (mucopolysaccharidosis type II) associated with unbalanced inactivation of the X chromosome in a karyotypically normal girl. Am J Hum Genet. 1991, 49: 289-297.PubMedPubMedCentral
5.
6.
Azofeifa J, Voit T, Hübner C, Cremer M: X-chromosome methylation in manifesting and healthy carriers of dystrophinopathies: concordance of activation ratios among first degree female relatives and skewed inactivation as cause of the affected phenotypes. Hum Genet. 1995, 96: 167-176. 10.1007/BF00207374.CrossRefPubMed
7.
Kubota T, Oga S, Ohashi H, Iwamoto Y, Fukushima Y: Borjeson-Forsman-Lehmann syndrome in a woman with skewed X-chromosome inactivation. Am J Med Genet. 1999, 26: 258-261.CrossRef
8.
Struewing JP, Pineda MA, Sherman ME, Lissowska J, Brinton LA, Peplonska B, Bardin-Mikolajczak A, Garcia-Closas M: Skewed X chromosome inactivation and early-onset breast cancer. J Med Genet. 2006, 43: 48-53. 10.1136/jmg.2005.039479.CrossRefPubMed
9.
Kristiansen M, Knudsen GP, Maguire P, Margolin S, Pedersen J, Lindblom A, Ørstavik KH: High incidence of skewed X chromosome inactivation in young patients with familial non-BRCA1/BRCA2 breast cancer. J Med Genet. 2005, 42: 877-880. 10.1136/jmg.2005.032433.CrossRefPubMedPubMedCentral
10.
Hickey T, Chandy A, Norman RJ: The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome. J Clin Endocrinol Metab. 2002, 87: 161-165. 10.1210/jcem.87.1.8137.CrossRefPubMed
11.
Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW: Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet. 1992, 51: 1229-1239.PubMedPubMedCentral
12.
Buchanan G, Yang M, Cheong A, Harris JM, Irvine RA, Lambert PF, Moore NL, Raynor M, Neufing PJ, Coetzee GA, Tilley WD: Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet. 2004, 13: 1677-1692. 10.1093/hmg/ddh181.CrossRefPubMed
13.
Nelson KA, Witte JS: Androgen receptor CAG repeats and prostate cancer. Am J Epidemiol. 2002, 155: 883-890. 10.1093/aje/155.10.883.CrossRefPubMed
14.
Santarosa M, Bidoli E, Gallo A, Steffan A, Boiocchi M, Viel A: Polymorphic CAG repeat length within the androgen receptor gene: identification of a subgroup of patients with increased risk of ovarian cancer. Oncol Rep. 2002, 9: 639-644.PubMed
15.
Suter NM, Malone KE, Daling JR, Doody DR, Ostrander EA: Androgen receptor (CAG)n and (GGC)n polymorphisms and breast cancer risk in a population-based case-control study of young women. Cancer Epidemiol Biomarkers Prev. 2003, 12: 127-3523.PubMed
16.
Haiman CA, Brown M, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Kantoff PW, Hunter DJ: The androgen receptor CAG repeat polymorphism and risk of breast cancer in the nurses’ health study. Cancer Res. 2002, 62: 1045-1049.PubMed
17.
Sasaki M, Sakuragi N, Dahiya R: The CAG repeats in exon 1 of the androgen receptor gene are significantly longer in endometrial cancer patients. Biochem Biophys Res Commun. 2003, 305: 1105-1108. 10.1016/S0006-291X(03)00883-0.CrossRefPubMed
18.
Rodríguez G, Bilbao C, Ramírez R, Falcón O, León L, Chirino R, Falcón O, Díaz BP, Rivero JF, Perucho M, Díaz-Chico BN, Díaz-Chico JC: Alleles with short CAG and GGN repeats in the androgen receptor gene are associated with benign endometrial cancer. Int J Cancer. 2006, 118: 1420-1425. 10.1002/ijc.21516.CrossRefPubMed
19.
Terry KL, De Vivo I, Titus-Ernstoff L, Shih MC, Cramer DW: Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. Cancer Res. 2005, 65: 5974-5981. 10.1158/0008-5472.CAN-04-3885.CrossRefPubMedPubMedCentral
20.
Choi C, Cho SH, Horikawa I, Berchuck A, Wang N, Cedrone E, Jhung SW, Lee JB, Kerr J, Chenevix-Trench G, Kim S, Barrett JC, Koi M: Loss of heterozygosity at chromosome segment Xq25–26.1 in advanced human ovarian carcinomas. Genes Chromosomes Cancer. 1997, 20: 234-242. 10.1002/(SICI)1098-2264(199711)20:3<234::AID-GCC3>3.0.CO;2-3.CrossRefPubMed
21.
Piao Z, Malkhosyan SR: Frequent loss Xq25 on the inactive X chromosome in primary breast carcinomas is associated with tumor grade and axillary lymph node metastasis. Genes Chromosomes Cancer. 2002, 33: 262-269. 10.1002/gcc.10024.CrossRefPubMed
22.
Ramal LM, Maleno I, Cabrera T, Collado A, Ferron A, Lopez-Nevot MA, Garrido F: Molecular strategies to define HLA haplotype loss in microdissected tumor cells. Hum Inmunol. 2000, 61: 1001-1012.CrossRef
23.
Lyon MF: Gene action in the X-chromosome of the mouse (Mus musculus). Nature. 1961, 190: 372-373. 10.1038/190372a0.CrossRefPubMed
24.
Buller RE, Sood AK, Lallas T, Buekers T, Skilling JS: Associated between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer. J Nat Cancer Inst. 1999, 91: 339-346. 10.1093/jnci/91.4.339.CrossRefPubMed
25.
Bowcock AM, Ruiz-Linares A, Tomfohrde J, Minch E, Kidd JR, Cavalli-Sforza LL: High resolution of human evolutionary trees with polymorphic microsatellites. Nature. 1994, 368: 455-457. 10.1038/368455a0.CrossRefPubMed
26.
Chêne L, Giroud C, Desgrandchamps F, Boccon-Gibod L, Cussenot O, Berthon P, Latil A: Extensive analysis of the 7q31 region in human prostate tumors supports TES as the best candidate tumor suppressor gene. Int J Cancer. 2004, 111: 798-804. 10.1002/ijc.20337.CrossRefPubMed
27.
Habuchi T, Yoshida O, Knowles MA: A novel candidate tumour suppressor locus at 9q32-33 in bladder cancer localization of the candidate region within a single 840 kb YAC. Hum Mol Genet. 1997, 6: 913-919. 10.1093/hmg/6.6.913.CrossRefPubMed
28.
Pestonjamasp PH, Mittra I: Analysis of BRCA1 involvement in breast cancer in Indian women. J Biosci. 2000, 25: 19-23. 10.1007/BF02985177.CrossRefPubMed
29.
Wang XW, Lin X, Klein CB, Bhamra RK, Lee YW, Costa M: A conserved region in human and Chinese hamster X chromosomes can induce cellular senescence of nickel-transformed Chinese hamster cell lines. Carcinogenesis. 1992, 13: 555-561. 10.1093/carcin/13.4.555.CrossRefPubMed
30.
Seki Y, Suico MA, Uto A, Hisatsune A, Shuto T, Isohama Y, Kai H: The ETS transcription factor MEF is a candidate tumor suppressor gene on the X chromosome. Cancer Res. 2002, 62: 6579-6586.PubMed
31.
Piao Z, Lee KS, Kim H, Perucho M, Malkhosyan S: Identification of novel deletion regions on chromosomes 2q and 6p in breast carcinomas by amplotype analysis. Genes Chromosomes Cancer. 2001, 30: 113-122. 10.1002/1098-2264(2000)9999:9999<::AID-GCC1069>3.0.CO;2-6.CrossRefPubMed
32.
Dunning AM, McBride S, Gregory J, Durocher F, Foster NA, Healey CS, Smith N, Pharoah PD, Luben RN, Easton DF, Ponder BA: No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer. Carcinogenesis. 1999, 20: 2131-2135. 10.1093/carcin/20.11.2131.CrossRefPubMed
Metadata
Title
Androgen receptor CAG repeats, non-random X chromosome inactivation, and loss of heterozygosity at Xq25 in relation to breast cancer risk
Authors
Hui-Tzu Chen
Yao-Chung Wu
Shou-Tung Chen
Hsien-Chang Tsai
Yi-Chih Chien
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-144

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?

Research article

Carnosine inhibits carbonic anhydrase IX-mediated extracellular acidosis and suppresses growth of HeLa tumor xenografts

Research article

Cell proliferation and apoptosis in rat mammary glands following combinational exposure to bisphenol A and genistein

Research article

The magnitude and characteristics of the population of cancer survivors: using population-based estimates of cancer prevalence to inform service planning for survivorship care

Research article

Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors

Research article

Colon and rectal cancer incidence and water trihalomethane concentrations in New South Wales, Australia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits